COMP <GO>
RPRX vs UNH // REVENUE GROWTH (YOY)
Royalty Pharma plc (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RPRX 7
— UNH 6
▲ REVENUE GROWTH (YOY) LEADER: RPRX
LAST: $66.52 (-0.98%) • MKT CAP: $38.25B
revenue-growth
5.10%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
revenue-growth
3.33%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.31% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 12.38% | -5.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.8x | 15.3x | +12.53 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 6.25% | +0.04 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 5.32% | +60.28 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 3.53% | +28.87 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.10% | 3.33% | +1.77 | RPRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 3.09 | -0.19 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RPRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.8 | 55.1 | +12.70 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.33 | +0.61 | RPRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 17.7x | +28.06 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $38.25B | $359.43B | -$321.18B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | UNH REV | RPRX GROSS % | UNH GROSS % | RPRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $447.57B | — | 88.7% | $2.38B | $16.07B |
| FY 2024 | $2.26B | $400.28B | — | 88.3% | $2.67B | $20.70B |
| FY 2023 | $2.35B | $371.62B | — | 89.6% | $2.88B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
UNH // BETA 0.33